Identifying non-invasive biomarker assays for lung cancer: what is an appropriate control group?
Addressing the issues faced in the ProtecT trial for patients with localized prostate cancer
10-year follow-up: the most effective treatment to ProtecT patients with localized prostate cancer?
Differentiating aggressive vs. non-aggressive prostate cancer: the MiCheck GPC1 biomarker test
An MRI-based approach to prostate cancer diagnosis: a urologist’s stance in the debate